Protein-polymer conjugation-moving beyond PEGylation

Area of Science:

• Materials Science
• Polymer Chemistry
• Biopharmaceutical Engineering

Background:

• Poly(ethylene glycol) (PEG)ylation is the established method for enhancing therapeutic protein and peptide drug efficacy.
• PEGylation improves drug circulation half-life and stability but presents limitations like non-degradability and potential immunogenicity.
• Growing concerns over PEG's drawbacks drive the search for advanced polymer alternatives in drug delivery.

Purpose of the Study:

• To review polymer conjugates as alternatives to PEG for peptide and protein drugs from a materials science viewpoint.
• To assess the progress and challenges in developing novel polymer materials for bioconjugation.
• To highlight the need for comprehensive in vivo evaluation of emerging PEG alternatives.

Main Methods:

• Literature review of materials science research on polymer conjugates for biotherapeutics.
• Analysis of current alternatives to poly(ethylene glycol) (PEG).
• Evaluation of the developmental stage and in vivo characteristics of alternative polymers.

Main Results:

• Several polymer materials show promise as alternatives to PEG in drug conjugation.
• Most alternative polymers are in early development stages, lacking extensive in vivo data.
• Key areas for investigation include in vivo distribution, degradation mechanisms, elimination routes, and immunogenicity.

Conclusions:

• While PEG remains the gold standard, its limitations necessitate the development of alternative polymer conjugates.
• Emerging polymer materials require rigorous in vivo testing to ascertain their safety and efficacy as PEG replacements.
• Further research is crucial to validate new polymers for biopharmaceutical applications, ensuring they overcome PEG's limitations.